Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × INDUSTRY × ibritumomab tiuxetan × Clear all

Phase

Phase 3 5 Phase 2 4 Phase 4 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Non-Hodgkin 1

Interventions

Zoledronic Acid 18 Bevacizumab 12 nilotinib 11 Docetaxel 11 Everolimus 10 Letrozole 9 Imatinib Mesylate 9 Erlotinib Hydrochloride 9 Drug Therapy 9 Capecitabine 9 pegfilgrastim 8 enzalutamide 8 Paclitaxel 8 icotinib 6 Trastuzumab 6 Rituximab 6 Prednisone 6 Oxycodone 6 Nivolumab 6 Imiquimod 6 Gemcitabine 6 Epoetin Alfa 6 Diclofenac 6 Cisplatin 6 Carboplatin 6 Anastrozole 6 exemestane 5 epoetin beta 5 Oxaliplatin 5 Leuprolide 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00168727 2023-08-23

Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma

Biogen

Phase 4 Completed

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon ⚡